The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | How to manage and report AEs associated with bispecific antibody treatment in myeloma
Heinz Ludwig, MD, Wilhelminen Cancer Research Institute, Vienna, Austria, discusses adverse events (AEs) associated with the use of bispecific antibodies in the treatment of multiple myeloma, including cytokine release syndrome (CRS) and infections. Prof. Ludwig emphasizes the importance of standardizing the reporting of infectious events, advising that clinicians should note each individual infection, type of infection, and grade of infection to better compare each event. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
